Results for tag: "Gastrointestinal Stromal Tumor Drug"

Gastrointestinal stromal tumor (GIST) is a rare type of cancer that affects the digestive system. It is the most common type of sarcoma, a type of cancer that develops in the connective tissues of the body. GISTs are typically treated with a combination of surgery, chemotherapy, and targeted therapy drugs. Targeted therapy drugs are designed to specifically target the cancer cells, while leaving healthy cells unharmed. The GIST drug market is a subset of the larger oncology drug market. It is composed of a variety of drugs, including imatinib, sunitinib, regorafenib, and trabectedin. These drugs are used to treat GISTs, as well as other types of sarcomas. The GIST drug market is expected to grow in the coming years, as new treatments are developed and approved. Some of the major companies in the GIST drug market include Novartis, Pfizer, Bayer, and Merck. These companies are involved in the development, manufacture, and marketing of GIST drugs. Other companies, such as Eli Lilly, AstraZeneca, and Bristol-Myers Squibb, are also involved in the GIST drug market. Show Less Read more